MXPA97009189A - Methods to inhibit the migration of cells of the smooth muscle vascu - Google Patents
Methods to inhibit the migration of cells of the smooth muscle vascuInfo
- Publication number
- MXPA97009189A MXPA97009189A MXPA/A/1997/009189A MX9709189A MXPA97009189A MX PA97009189 A MXPA97009189 A MX PA97009189A MX 9709189 A MX9709189 A MX 9709189A MX PA97009189 A MXPA97009189 A MX PA97009189A
- Authority
- MX
- Mexico
- Prior art keywords
- migration
- smooth muscle
- compound
- cells
- muscle cells
- Prior art date
Links
- 230000005012 migration Effects 0.000 title claims abstract description 24
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 239000011780 sodium chloride Substances 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims abstract description 10
- -1 pyrrolidino, hexamethyleneimino Chemical group 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 241000124008 Mammalia Species 0.000 claims abstract 3
- 210000004027 cells Anatomy 0.000 claims description 16
- 200000000008 restenosis Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 201000001320 atherosclerosis Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000029578 entry into host Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000003211 malignant Effects 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000008177 pharmaceutical agent Substances 0.000 description 10
- 239000000969 carrier Substances 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 5
- 229960004622 Raloxifene Drugs 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 210000000709 Aorta Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000007963 capsule composition Substances 0.000 description 4
- 238000007887 coronary angioplasty Methods 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- 230000003902 lesions Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000015590 smooth muscle cell migration Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 206010038563 Reocclusion Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 210000004351 Coronary Vessels Anatomy 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N Cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 229960005322 Streptomycin Drugs 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M 2,3-dimethylbenzenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-M 2,3-dinitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-M 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-M 2-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-M 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-M Acetylsalicylate Chemical compound CC(=O)OC1=CC=CC=C1C([O-])=O BSYNRYMUTXBXSQ-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 206010053261 Coronary artery reocclusion Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 210000003038 Endothelium Anatomy 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Enoxaparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N Epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-M N-benzoylglycinate Chemical compound [O-]C(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-M 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N Peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229960003531 Phenolsulfonphthalein Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- HMGCGUWFPZVPEK-UHFFFAOYSA-M [O-]C(=O)C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=C1 Chemical compound [O-]C(=O)C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=C1 HMGCGUWFPZVPEK-UHFFFAOYSA-M 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000000274 adsorptive Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 201000000057 coronary stenosis Diseases 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical group 0.000 description 1
- 150000005195 diethylbenzenes Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229960004723 phenylbutyrate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Abstract
Methods are provided for inhibiting the migration of vascular smooth muscle cells, which comprises administering to a human or other mammal in need of treatment an effective amount of a compound having the formula (I) wherein R1 and R3 are independently hydrogen. CH3, (a) or (b), wherein Ar is optionally substituted phenyl, R2 is pyrrolidino, hexamethyleneimino or piperidino, and pharmaceutically acceptable salts and solvates thereof.
Description
METHODS TO INHIBIT MASSAGE MUSCLE SMOOTH VASCULAR
Deactivation gives the Invention
ftnMedmet flffi a Invention
Cell migration plays an important role in wound healing, inflammation, in adult respiratory disease syndrome and in the invasion of malignant cancers (Savani et al., J, Clin, Invest. 95: 1158-1168,
nineteen ninety five; Kullmann et al. , Am J. Respir. Cell. Mol. Biol. 8:
83-88, 1993; Brooks et al. , Cell: 79, 1157-1164, 1994). Migration of vascular smooth muscle cells from the media to the intima plays a critical role in neointima formation leading to the pathogenesis of vascular diseases such as atherosclerosis, post-PTCA restenosis and atherosclerosis by vein shunting (Jackson et al. ., Arteriesclerosis and Thrombosis 13: 1218-1226, 1993;
Brown et al., Cardiovascular Res. 28: 1815-1820, 1995; Bell and Madri, Am. J. Pathol. 137: 7-12, 1990). It has been found that the use of antibodies to growth factors that stimulate the migration of smooth muscle cells or peptides that block cell migration mediated
REF: 26043 per integrin inhibit the formation of neointima and animal models of vascular damage (Ferns et al., Science 253: 1129-1132, 1991., Choi et al., J. Vasc. Surg. 19: 125-135, 1994 ). Vascular restenosis after percutaneous transluminal coronary angioplasty (PTCA) has been shown to be a tissue response characterized by an early and a delayed phase. Thrombosis and / or vasospasm may contribute to the early phase occurring from hours to days after PTCA. The late phase seems to be dominated by SMC migration, vascular proliferation and remodeling. In this disease, the increased accumulation of SMC by migration of the intima media contributes significantly to the pathogenesis of the disease. Excessive proliferation and migration of vascular smooth muscle cells may be the main mechanism for coronary artery reocclusion after PTCA, atherectomy, angioplasty. laser and graft surgery for arterial bypass. See "Intimal Proliferation of Smooth Muscle Cells as an Explanation for Recurring Coronary Artery Stenosis after Percutaneous Transluminal Coronary Angioplasty," Austin et al. , Journal of the American College of Cardiology 8: 369-375 (August 1985). Vascular restenosis remains a major long-term complication after coronary artery surgery by percutaneous transluminal coronary angioplasty (PTCA), atherectomy, laser angioplasty, and graft surgery for arterial bypass. In approximately 35% of patients who undergo PTCA, reocclusion occurs within three to six months after the procedure. Current strategies for treating vascular restenosis include mechanical intervention by devices such as stents or pharmacological therapies including heparin, low molecular weight heparin, cuolin, aspirin, fish oil, calcium antagonists, steroids and prostacyclin. These strategies have not eliminated the reocclusion rate and have been ineffective for the treatment and prevention of vascular restenosis. See "Prevention of Restenosis after Percutaneous Transluminal Coronary
Angioplasty: The Search for a 'Magic Bullet', "Hermans et al., American Heart Journal 122: 171-187 (July 1991) In the pathogenesis of restenosis there is an excessive proliferation and migration of cells as a result of factors of growth mediated by cellular constituents in the blood and in the wall of the damaged arterial vessel which mediates the proliferation of smooth muscle cells in vascular restenosis Agents that inhibit the migration of smooth muscle cells are useful in the treatment and prevention of The present invention provides the use of compounds as inhibitors for the migration of smooth muscle cells.
BRIEF DESCRIPTION OF THE INVENTION
The invention provides a method for inhibiting the migration of vascular smooth muscle cells in a human or other mammalian subject comprising administering to the subject a pharmaceutically effective dose of a compound of the formula
wherein R1 and R3 are independently hydrogen, -CH3, or
(Alkyl of C-C) 1 6
Ar
wherein Ar is optionally substituted phenyl; R2 is pyrrolidino, hexamethyleneimino or piperidino; and pharmaceutically acceptable salts and solvates thereof.
DESCRIPTION PETFTT.T.ftPft OF THE IMVENCIQN
The present invention relates to the discovery that a select group of compounds, those of formula I, are useful for inhibiting the migration of vascular smooth muscle cells. The methods of treatment provided by this invention are practiced by administering to the human or other animal in need of a dose of a compound of formula I or II, or a pharmaceutically acceptable salt or solvate thereof, which is effective to inhibit migration of vascular smooth muscle cells. The term "inhibit" is defined to include its generally accepted meaning, which includes prophylactically treating a human subject to prevent migration of smooth muscle cells, and maintaining verification and / or treatment of smooth muscle cell migration. existing. As such, the present method includes both medical therapeutic and prophylactic treatment, as appropriate. Generally, the compound is formulated with common excipients, diluents or carriers, and compressed into tablets or formulated as elixirs or solutions for convenient oral administration, or administered intramuscularly or intravenously. The compounds can be administered transdermally and can be formulated as sustained release dosage forms and the like. The compounds of formula I used in the methods of the present invention can be manufactured according to established procedures, such as those detailed in US Pat. Nos. 4,133,814, 4,418,068 and 4,380,635, all of which are incorporated herein by reference. reference. In general, processes begin with benzo [b] thiophene having a β-hydroxyl group and a 2- (4-hydroxyphenyl) group. The starting compound is protected, alkylated and deprotected to form the compounds of formula I. Examples of the preparation of such compounds are provided in the North American patents described above. The use of the following compounds is included in the invention:
(IA)
(IB) Substituted phenyl includes phenyl substituted once or twice with C 1 -C 6 alkyl, C 1 -C 4 alkoxy, hydroxy, nitro, chloro, fluoro or tri (chloro or fluoro) methyl. The compounds used in the methods of this invention form pharmaceutically acceptable base acid addition salts with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the like. Salts derived from organic acids, such as monoaliphatic and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkane and hydroxyalkanedioic acids, aromatic acids, aliphatics and aromatic sulfonic acids can also be used. Such pharmaceutically acceptable salts, therefore, include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, β- hydroxybutyrate, butyl-1,4-dioate, hexin-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycolate, heptanoate, hippurate, lactate, malate, maleate, hydroxyalate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethane sulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2 sulfonate, p-toluenesulfonate, xylene sulfonate, tartrate and the like. A preferred salt is a hydrochloride salt. The pharmaceutically acceptable acid addition salts are typically produced by reacting a compound of formula I with an equimolar or excess amount of acid. The reagents are generally combined in a mutual solvent such as diethyl ether or benzene. The salt is usually separated by precipitation from the solution in about 1 hour to 10 days and can be isolated by filtration, or the solvent can be removed by distillation by conventional means. Bases commonly used for the formation of salts include ammonium hydroxide and alkali metal or alkaline earth metal hydroxide, carbonates and bicarbonates, as well as aliphatic and aromatic amines, aliphatic diamines and hydroxyalkylamines. Bases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylenediamine, cyclohexylamine and ethanolamine. The pharmaceutically acceptable salts generally have improved solubility characteristics as compared to the compound from which they are derived, and therefore are often more susceptible to formulation as liquids or emulsions. The pharmaceutical formulations can be prepared by methods known in the art. For example, the compounds can be formulated with common excipients, diluents or carriers and can be constituted into tablets, capsules, suspensions, powders and the like. Examples of excipients, diluents and carriers that are suitable for such formulations include the following: fillers and solvents such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethylcellulose and other cellulose derivatives, alginates, gelatin and polyvinylpyrrolidone; wetting agents such as glycerol; disintegrating agents such as agar, calcium carbonate and sodium bicarbonate; agents for delaying dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surfactants such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate and solid polyethylene glycols. The compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions suitable for parenteral administration, for example, intramuscularly, subcutaneously or intravenously. Additionally, the compounds are suitable for formulation as sustained release dosage forms and the like. The formulations may be constituted so as to release the active ingredient uniquely or preferably in a defined part of the intestinal tract, possibly over a period of time. The coatings, envelopes and protective matrices can be made, for example, from polymeric or silk materials. The particular dosage of a compound of formula I required to inhibit the migration of smooth muscle cells according to this invention will depend on the severity of the condition, the route of administration and related factors that will be decided by the attending physician. Generally, effective daily accepted dosages will be between about 0.1 to about 1000 mg / day, and more typically from about 50 to about 200 mg / day. Such dosages will be administered to a subject in need of treatment from once to approximately three times each day, or more frequently as necessary to effectively inhibit the migration of smooth muscle cells. The local delivery of inhibitory amounts of the active compound for the treatment of vascular smooth muscle cell migration or restenosis can be by various techniques with which the compound is administered at or near the affected site. The examples of local supply techniques are not considered as limiting but as illustrative of the available techniques. Examples include local delivery catheters, site specific carriers, implants, direct injection or direct applications. The local supply by a catheter allows the administration of a pharmaceutical agent directly in the affected lesion. Examples of local delivery using a balloon catheter are described in EPO 383 492 A2 and U.S. Patent No. 4,636,195 (January 13, 1987).
Local delivery by an implant describes the surgical placement of a matrix containing the pharmaceutical agent in the lesion. The implanted matrix releases the pharmaceutical agent by diffusion, chemical reaction or solvent activators. Lange, Science 249: 1527-1533 (September 1990). An example of local delivery by an implant is the use of a stent. The stents are designed to mechanically avoid the collapse or reocclusion of the coronary arteries. The incorporation of a pharmaceutical agent in the stent delivers a medication directly to the affected site. Local supply by this technique is described in Kohn, Pharmaceutical Technology (October 1990). Another example is a delivery system in which a polymer containing the pharmaceutical agent is injected into the lesion in liquid form. The polymer is then cured to form an implant in situ. This technique is described in PCT WO 90/03768 (Donn, April 19, 1990). Another example is the delivery of a pharmaceutical agent by the polymeric endoluminal seal. This technique uses a catheter to apply a polymer implant to the inner surface of the lumen. The pharmaceutical agent incorporated in the biodegradable polymer implant in this manner is released at the surgical site. This method is described in PCT WO 90/01969 (Schindler, August 23, 1989). A final example of local delivery by an implant is the direct injection of vesicles or microparticles into the affected site. These microparticles can be constituted by substances such as proteins, lipids, carbohydrates or synthetic polymers. These microparticles have the pharmaceutical agent incorporated through the microparticle or the microparticle as a coating. Delivery systems that incorporate microparticles are described in Lange, Science 249: 1527-1533 (September 1990) and Mathiowitz, et al. , J. App. Poly. Sci. , 26: 809 (1981). Local delivery by site-specific carriers describes the binding of the pharmaceutical agent to a carrier which will direct the drug to the lesion. Examples of the delivery technique include the use of carriers such as a protein ligand or a monoclonal antibody. Lange, Science 249: 1527-1533 (September). Local supply by direct administration includes the use of topical applications. An example of a local delivery by direct application is the application of the pharmaceutical agent directly to the arterial bypass graft during the surgical procedure.
It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is usual in the administration of pharmaceutical substances having a basic group, such as the piperidino ring. It is also advantageous to administer such a compound orally to an elderly human (e.g., a post-menopausal woman). For these purposes the following oral dosage forms are available.
Foraulacianes
In the formulations that follow, "active ingredient" means a compound of formula I.
Formulation 1: Gelatin capsules
Hard gelatin capsules are prepared using the following:
The ingredients are mixed, passed through a No. 45 mesh North American sieve and filled into hard gelatin capsules. Examples of capsule formulations specific to the compound of formula I in which the compound is raloxifene, include those shown below.
Formulation 2; Raloxifene capsule
Formulation; Raloxifene capsule Formulation 4; Raloxifene capsule
Formulation 5: Raloxifene Capsule
The above specific formulations may change in accordance with the reasonable variations provided. A tablet formulation is prepared using the following ingredients:
Formulation 6 Tablets
Acid stearate 15
The components are mixed and compressed to form tablets. Alternatively, tablets are made as follows, each containing 0.1 - 1000 mg of active ingredient:
Formulation 7: Tablets
The active ingredient, starch and cellulose are passed through an American mesh screen
No. 45 and mix carefully. The polyvinylpyrrolidone solution is mixed with the resulting powders which are then passed through a No. 14 mesh North American sieve. The granules produced in this way are dried at 50 ° -60 ° C and passed through the a North American sieve of mesh No. 18. Sodium carboxymethyl starch, magnesium stearate and talcum, which are previously passed through a North American sieve No. 60, then add the granules, which, after mixing, compress in a tabletting machine to produce tablets. Suspensions are prepared as indicated below, each containing 0.1 - 1000 mg of medication per 5 ml dose:
Formulation 8: Suspensions
The medicament is passed through a No. 45 mesh North American sieve and mixed with sodium carboxymethyl cellulose and syrup to form a smooth or regular paste. The benzoic acid solution, flavor and color are diluted with a little water, and added with agitation. Subsequently enough water is added to produce the required volume.
PROOF PROCEDURE
The compounds of the invention have the ability to inhibit the migration of vascular smooth cells, as evidenced by the following.
Smooth muscle cells of porcine aorta.
Porcine aorta is obtained from castrated male pigs freshly slaughtered in a local trail. Smooth muscle cells are prepared using a procedure similar to that previously described (Bonin et al., 1989). Briefly, the aorta is cut longitudinally, and the endothelium is removed by gently scraping the surface of the lumen with a razor. The aorta is then washed several times in sterile growth medium consisting of Eagle's medium modified by Dubecco (DMEM), 10% fetal bovine serum, L-glutamine (2 mM), penicillin (100 U / ml) and streptomycin ( 100 μg / ml). The strips of medium smooth muscle cells are then detached from the adventitia and cut into 1 - 2 mm pieces. The explants are placed in 24-well culture vessels containing the above growth medium. The growth of the cells of the explants is observed in the following 5-7 days. After 10-14 days, the explants are removed, the cells are trypsinized and subcultured in T75 flasks containing 15 ml of the growth medium.
Human smooth muscle cells
Human coronary and aortic smooth muscle cells are purchased from Clonetics Corporation (San Diego, CA). Both cell types are grown in growth medium as described for porcine smooth muscle cells.
Smooth muscle cell migration assay
The directed migration of smooth muscle cells, derived from porcine and human arteries, to a gradient of platelet-derived growth factor is carried out using a modified Boyden chamber using a 96-well piercing system and polycarbonate filter with pores of 8 μm (Neuro Probé, Inc., Cabin John, NJ). Smooth muscle cells growing in T75 flasks are transferred to Dubecco-modified Eagle medium free of phenol / F12 medium (DMEM / F-12), containing 2% fetal bovine serum, L-glutamine (2 mM) , penicillin (100 U / ml) and streptomycin (100 μg / ml). After 24 hours, the cells are trypsinized using phenol-free red / EDTA trypsin (Gibco, BRL). The cells (2.5 x 10"6 cells / ml) are suspended in DMEM / F12 free of phenol red containing 1% platelet poor plasma, and various concentrations of the compounds of formula I. 100 μl of cell suspension is added. The upper wells of the modified Boyden chamber The lower chamber wells are filled with 43 μl of DMEM / F12 containing 1% platelet-poor plasma, 5 ng / ml PDGF and varying concentrations of the compounds. they are incubated at 37 ° C in 5% C02 for 5 hours.The migration membrane is removed from the chamber and the cells on the upper side of the membrane are separated with a cotton swab.The cells migrate to the lower side of the membrane, they are fixed in methanol and stained with Diff-Quick staining solution (Baxter). Cell migration is quantified spectrophotometrically using a microtiter plate reader (ThermoMax, Molecular Dynamics, Inc.) or by counting cells in a 40X high power field (HPF) using an inverted microscope (Nikon, Inc.). For experiments involving the re-incubation of cells with the compound, the drug is placed in the pretreatment medium at the indicated concentrations, in separate flasks, and incubated for 18 hours. The test conditions of the cells in these pretreatment experiments are exactly the same as those used in the experiments described for acute drug effects.
Table I
Stimulation of Migration of Smooth Muscle Cells
Porcine Aortic (SMC) by Growth Factor Platelet Derivatives (PDGF)
Table II
Inhibition of Swine Atrial SMC Migration Induced by PDGF by Compound A * and Migration of β-Estradiol SMC (D.O. 650 nm)
* Compound A is of the formula I, wherein Rx and R3 are hydrogen and R2 pyrrolidino. The activity in the above indicates that the compounds of the invention have potential in the inhibition of vascular smooth muscle cell migration and its effects. It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention. Having described the invention as above, property is claimed as contained in the following:
Claims (4)
1. Use of a compound having the formula (I) for the manufacture of a medicament for inhibiting the migration of vascular smooth muscle cells comprising administering to a human or other mammal in need of treatment an effective amount of said compound wherein R1 and R3 are independently hydrogen, -CH3, (Alkyl of C - Ar wherein Ar is optionally substituted phenyl; R2 is pyrrolidino, hexamethyleneimino or piperidino; and pharmaceutically acceptable salts and solvates thereof.
2. The use according to claim 1, characterized in that the compound is the hydrochloride salt thereof.
3. The use according to claim 1, characterized in that the compound is or its hydrochloride salt.
4. The use according to claim 1, characterized in that the administration is for inhibition of atherosclerosis, restenosis, inflammation or invasion by malignant cancer cells. THE INVENTION Methods for inhibiting the migration of vascular smooth muscle cells are provided, which comprises administering to a human or other mammal in need of treatment an effective amount of a compound having the formula (I) wherein R x and R 3 are independently hydrogen, -CH3, (a) or (b), wherein Ar is optionally substituted phenyl; R2 is pyrrolidino, hexamethyleneimino or piperidino; and pharmaceutically acceptable salts and solvates thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/457,700 US5622975A (en) | 1995-06-01 | 1995-06-01 | Methods for inhibiting vascular smooth muscle cell migration |
US08457700 | 1995-06-01 | ||
PCT/US1996/008037 WO1996038145A1 (en) | 1995-06-01 | 1996-05-30 | Methods for inhibiting vascular smooth muscle cell migration |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9709189A MX9709189A (en) | 1998-03-31 |
MXPA97009189A true MXPA97009189A (en) | 1998-10-15 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0652003B1 (en) | Methods for inhibiting smooth muscle cell proliferation and restinosis | |
AU707756B2 (en) | Methods for inhibiting vascular smooth muscle cell migration | |
AU693021B2 (en) | Methods of inhibiting cell-cell adhesion | |
EP0681836A1 (en) | Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives | |
RU2127592C1 (en) | Agent for inhibition of oxidation of low density lipids and atherosclerosis suppression | |
JP5681227B2 (en) | Therapeutic agents and pharmaceutical compositions containing methylphenidate derivatives | |
EP0682947A1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
AU716064B2 (en) | Methods of increasing nitric oxide synthesis | |
EA001003B1 (en) | Method of inhibiting plasminogen activator inhibitor 1 | |
MXPA97009189A (en) | Methods to inhibit the migration of cells of the smooth muscle vascu | |
TW391964B (en) | Pharmaceutical compositions for inhibiting vascular smooth muscle cell migration | |
EA001931B1 (en) | Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the treatment or prevention of restenosis | |
KR20110036024A (en) | Pharmaceutical composition and stent for preventing and treating late stent thrombosis | |
MXPA97006072A (en) | Methods of inhibition of cell-cell adhesion |